The author is a Reuters Breakingviews columnist. The opinions expressed are his own.
By Jeffrey Goldfarb
NEW YORK, Dec 13 (Reuters Breakingviews) - Blank-check hype helped elevate Blade’s $825 mln valuation until the euphoria landed with a thud. Since then, the company has found more success transporting organs than Manhattan or Monaco jet-setters. The promise of quieter electric aircraft is another reason to go for a ride.
Full view will be published shortly.
Follow @jgfarb on X
CONTEXT NEWS
Blade Air Mobility said on Nov. 12 that its revenue increased about 5% to $75 million in the third quarter from a year earlier and that its passenger business achieved positive adjusted EBITDA on a trailing 12-month basis ahead of earlier guidance to do so by the end of 2025.
The company, which transports passengers and human organs for transplant by helicopter, expects to generate $240 million to $250 million of revenue in 2024, as well as a double-digit rate of revenue growth in its medical division in 2025.
(Editing by Jonathan Guilford and Pranav Kiran)
((For previous columns by the author, Reuters customers can click on GOLDFARB/jeffrey.goldfarb@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。